Mural Oncology plc(MURA)Earnings, Financials & Key Ratios
MURA•NASDAQ
$2.04
Price updated Jun 20, 2026
AboutMural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.Show more
- Revenue$0
- EBITDA-$135M+29.8%
- Net Income-$129M+38.0%
- EPS (Diluted)-7.58+39.0%
- ROE-63.57%+62.9%
MURA Price & Volume
Mural Oncology plc (MURA) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Threaten Capital Runway Sustainability
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding exhaustion
Key Thesis Takeaways
- Mural Oncology faces a precarious financial outlook as it continues to fund late-stage clinical trials like ARTISTRY-7 without any commercial revenue streams.
- The company's reliance on an asset-light model has resulted in a rapid depletion of its capital base, with total assets contracting from $301.7 million in 2023Q4 to $65.8 million by 2025Q3.
- Investors should monitor the company's ability to secure additional funding, as the current burn rate and lack of operating leverage suggest that liquidity may become a critical constraint within the coming quarters.
Verdict Logic
the company's cash balance has declined to $58.9 million as of 2025Q3, which may necessitate dilutive capital market intervention to sustain its ongoing clinical development programs.
MURA Growth Metrics
Mural Oncology plc (MURA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM22.55%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM24.18%
Return on Capital
10 Years-3751.32%
5 Years-3751.32%
3 Years-1864.07%
Last Year-66.48%
Peers Comparison
Key metrics vs top competitors for Mural Oncology plc (MURA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.04 | $35.38M | -0.27 | — | — | -63.57% | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — | |
| $35.26 | $2.35B | -9.04 | -78.63% | -34596.22% | -50.72% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $3.03 | $126.18M | -891.18 | 10.37% | 52.16% | — | — | |
| $74.96 | $8.89B | 29.28 | 37.55% | 23.13% | 126.27% | — |
Compare MURA vs Peers
Mural Oncology plc (MURA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when MURA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MURA Frequently Asked Questions
Mural Oncology plc (MURA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is MURA profitable?
Mural Oncology plc (MURA) reported a net loss of $119.1M for fiscal year 2024.
Dividend & Returns
What is MURA's return on equity?
Mural Oncology plc (MURA) has a return on equity (ROE) of -63.6%. Negative ROE indicates the company is unprofitable.
What is Mural Oncology plc's free cash flow?
Mural Oncology plc (MURA) had negative free cash flow of $118.5M in fiscal year 2024, likely due to heavy capital investments.